
USD
$0.00
(0.00%
)At Close (As of Dec 9, 2025)
$39.25M
Market Cap
-
P/E Ratio
-0.23
EPS
$19.51
52 Week High
$0.51
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | - |
| Total Revenue | $0 |
| Cost Of Revenue | - |
| Costof Goods And Services Sold | - |
| Operating Income | -$3.1M |
| Selling General And Administrative | $2.6M |
| Research And Development | $493K |
| Operating Expenses | $3.1M |
| Investment Income Net | - |
| Net Interest Income | -$243K |
| Interest Income | $5.6K |
| Interest Expense | $248K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | - |
| Income Before Tax | -$2.4M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$2.4M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$3.1M |
| Ebitda | -$2.2M |
| Net Income | -$2.4M |
| Field | Value (USD) |
|---|---|
| Total Assets | $6.2M |
| Total Current Assets | $4.7M |
| Cash And Cash Equivalents At Carrying Value | $3.8M |
| Cash And Short Term Investments | $3.8M |
| Inventory | - |
| Current Net Receivables | - |
| Total Non Current Assets | $1.6M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | - |
| Intangible Assets Excluding Goodwill | - |
| Goodwill | - |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | - |
| Other Current Assets | $881K |
| Other Non Current Assets | - |
| Total Liabilities | $2M |
| Total Current Liabilities | $2M |
| Current Accounts Payable | $279K |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $197K |
| Total Non Current Liabilities | $21K |
| Capital Lease Obligations | $71K |
| Long Term Debt | - |
| Current Long Term Debt | $146K |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $218K |
| Other Current Liabilities | $1.5M |
| Other Non Current Liabilities | - |
| Total Shareholder Equity | $4.2M |
| Treasury Stock | - |
| Retained Earnings | -$26M |
| Common Stock | $3.3K |
| Common Stock Shares Outstanding | $29M |
| Field | Value (USD) |
|---|---|
| Gross Profit | - |
| Total Revenue | $0 |
| Cost Of Revenue | - |
| Costof Goods And Services Sold | - |
| Operating Income | -$3.1M |
| Selling General And Administrative | $2.6M |
| Research And Development | $493K |
| Operating Expenses | $3.1M |
| Investment Income Net | - |
| Net Interest Income | -$243K |
| Interest Income | $5.6K |
| Interest Expense | $248K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | - |
| Income Before Tax | -$2.4M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$2.4M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$3.1M |
| Ebitda | -$2.2M |
| Net Income | -$2.4M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Jupiter Neurosciences, Inc. is a clinical-stage biotechnology company headquartered in Jupiter, Florida, specializing in the development of innovative pharmaceutical therapies targeting neuroinflammation-related disorders through its proprietary resveratrol platform. The company is focused on advancing its robust drug development pipeline, aimed at providing breakthrough treatments for various neurological conditions amid a growing demand for effective neurotherapeutics. With a strong commitment to research and development, Jupiter Neurosciences is well-positioned to make significant contributions to the pharmaceutical landscape and enhance patient outcomes in neurology.